By : 

^*Aml S Nasr(M.D)¹, Hoda M El Azizy (M.D) ², Noha M  El Husseiny(M.D) ³ ,Samar S Youssef (PhD)⁴

¹ Clinical Pathology Department , Faculty of Medicine, Cairo University, Egypt.

² Medical biochemistry Department, Faculty of Medicine, Cairo University, Egypt.

³  Internal medicine Department , Cairo University, Egypt.

⁴Microbial biotechnology Department, National Research Center, Giza, Egypt.

Abstract

Background: Acute myeloid leukemia (AML) is a highly fatal  disease occurring due to  proliferation  and accumulation of myeloid progenitor cells. Th17 cells had been claimed by many studies to play a role in the development  of AML. Aim Of work: This work aimed to detect possible role of IL 17 F and IL 23  gene polymorphisms in pathogensis of AML ,relation to prognosis and response to treatment. Subjects , materials and methods: This study was done on 68 patients with newly diagnosed AML (as a patient group) ,together with  56 matched healthy volunteers( control group). IL 17 F and IL 23  gene polymorphisms were genotyped by real time polymerase chain reaction(Real time PCR). Results: No significant differences were detected between patients and controls in respect to   IL 17 genotype distribution , there was statistically significant differences  between patients and controls regarding  IL 23 genotype distribution. No statistically significant relation was found beween interleukin 17 and interleukin 23  and any  of the bad prognostic markers. Conclusion: We concluded that IL23 gene polymorphism could be considered as independent risk factor  in the pathogenesis of AML ,while  we could not prove that IL 17 gene polymorphism has a role in the development of AML.

IL‑17F and IL- 23 gene polymorphism in patients with acute myeloid leukemia, an Egyptian study (1)

Download PDF